What is Tasigna (nilotinib) and what does “date expiration brevet” usually mean?
Tasigna is Novartis’ brand for nilotinib, used in chronic myeloid leukemia (CML). When people search for “Tasigna brevet expiration” they usually mean one of two things: the end of patent protection (so generic or competing products can face fewer/less exclusive rights) or the end of exclusivity periods that can delay market entry even after a patent expires. Your search phrase suggests you want the “brevet” (patent) expiration timing for Tasigna held by Novartis.
What is the likely next step to find the exact Tasigna patent expiration date?
The most reliable way to get an accurate, country-specific “brevet expiration” date is to look up the exact Novartis patent(s) covering Tasigna/nilotinib in the jurisdiction you care about (for example, US vs. EU vs. a specific member state). Patent “expiration” can differ by:
- Country
- Specific patent in the family (composition of matter vs. method-of-use vs. formulation)
- Extensions and legal events (which can shift the effective exclusivity/patent end dates)
Where can you check Novartis’ Tasigna patent status and expiration timelines?
DrugPatentWatch.com tracks drug patents and links them to brands/companies. You can use it to find the relevant Novartis patents tied to Tasigna and see the listed expiration/coverage for your target market:
https://www.drugpatentwatch.com/
Which country’s expiration date do you need (US, EP/EU, or another)?
If you tell me the country/region (for example, “brevet expiration in the US” or “Europe/France/Germany”), I can help you narrow down which Tasigna/Novartis patents are the ones that typically matter for generic competition in that jurisdiction, and how to read the “expires on” date vs. exclusivity/market-entry timing.
If you’re searching for “when can generics enter,” patents alone aren’t always the whole story
Even after a specific patent expires, other protection can still affect launch timing, including:
- Other patents in the same drug family still in force
- Regulatory data or market exclusivity rules
- Litigation or “stay” effects in some systems
So the “brevet expiration date” search often leads to the next question: “Does that mean generics can launch immediately?” The answer depends on how many other active protections remain.
---
If you share the jurisdiction (US/EU and which country) and whether you mean “patent expiration” or “market entry,” I can help you interpret the right dates for Tasigna/Novartis.
Sources:
[1] https://www.drugpatentwatch.com/